Make the molecules that matter

We sought the scientific expertise within the Cresset Discovery Services team to utilize their novel field and shape-based virtual screening methods in Blaze™, and their proprietary Electrostatic Complementarity™ technique to help identify a backup series for our target effectively and efficiently. Ultimately we identified 9 novel chemotypes that were clearly distinct to those arising from docking and pharmacophore virtual screening approaches, which was an exciting outcome for us.

Dr Zara Sands, Head of CADD and Informatics, Confo Therapeutics, Belgium

Through the work presented to us I was particularly impressed with the data management and visualization within Forge, so the next step was for us to use it in-house. We will use Forge alongside our continuing consulting work with Cresset to aid in the development of our understanding of the SAR and design of future antifungal agents.

Dr Graham Sibley, Head of Chemistry, F2G, UK

We really like the powerful combination of excellent software tools and molecular design expertise which we get from working with Cresset.

Dr Graham Sibley, Head of Chemistry, F2G, UK

Cresset is a valuable partner in our drug discovery programs. Their deep knowledge of computational chemistry and its application to drug discovery is enabling us to progress multiple projects across a wide range of target classes very quickly and cost-effectively. Cresset has consistently delivered insightful support to our drug discovery efforts. In our experience, their knowledge, responsiveness and collaborative approach have set them apart from their competitors.

CEO, Pharmaceutical company, UK

Cresset Discovery Services’ computational experience and high standard of scientific support is ideally suited to help drive the next stage of this project.

Dr Richard Boyce, Senior Director of Research at PhoreMost